Characterization of antibody-drug conjugates using next-generation technology

Antibody-drug conjugates (ADCs) are one of the rapidly growing classes of the biopharmaceutical market and formed by the conjugation of various drug species to a monoclonal antibody. Effective characterization methods for ADCs are needed to ensure the stability and efficacy of the drug because the complexity and heterogeneity of the ADC structure itself increase the process of linking the payload to the protein backbone.